{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Six and twelve-month CNS progression-free survival rate.","groups":[{"description":"Rituximab: 375 mg/m2 IV, days 1, 3, and 5 Temozolomide: 150 mg/m2 PO, days 1-5\n\nRituximab plus Temozolomide: Treatment cycles will be repeated every 14 days (2 weeks) for the lead-in portion. If no prohibitive toxicities are observed in the first 6 patients during the first 2 treatment cycles, the study will continue enrolling patients. Treatment cycles for the Phase II portion will be repeated every 14 days (2 weeks) for a total of 12 cycles.","id":"OG000","title":"Rituximab Plus Temozolomide"}],"populationDescription":"The study closed early due to slow accrual; outcome measure not reached.","reportingStatus":"POSTED","timeFrame":"6 and 12 months","title":"Progression Free Survival (PFS)","type":"SECONDARY"}